COMMUNIQUÉS West-GlobeNewswire

Kura Oncology Reports First Quarter 2024 Financial Results
02/05/2024
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data [...]
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
02/05/2024
Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage [...]
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
02/05/2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will [...]
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
02/05/2024
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program [...]
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
02/05/2024
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most [...]
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
02/05/2024
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine [...]
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
02/05/2024
Commercial launch of INPEFA ® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of [...]
The Joint Corp. Reports First Quarter 2024 Financial Results
02/05/2024
- Grew Q1 2024 Revenue 5%, System-wide Sales 9%, and System-wide Comp Sales 3% vs. Q1 2023 - - Opened 23 Franchised Clinics, Increasing Clinic Count to 954 at March 31, 2024 - - Sold 15 Franchise Licenses, Tripling [...]
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
02/05/2024
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to [...]
OrthoPediatrics Corp. Receives “Breakthrough Device” Designation from FDA for eLLi™ Growing Rod System for Pediatric Patients with Scoliosis
02/05/2024
WARSAW, Ind., May 02, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has received the [...]
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
02/05/2024
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
02/05/2024
SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its first quarter 2024 financial [...]
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
02/05/2024
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, [...]
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
02/05/2024
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease- [...]
Codexis Reports First Quarter 2024 Financial Results
02/05/2024
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final [...]
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
02/05/2024
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Completion of rolling biologics [...]
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
02/05/2024
Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately [...]
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
02/05/2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today [...]
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
02/05/2024
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of [...]

Pages